Phase II Study of Taselisib in PIK3CA -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
Ian E KropOpeyemi A JagedeJuneko E Grilley OlsonJosh D LauringEdith P MitchellJames A ZwiebelRobert C GrayVictoria WangLisa Meier McShaneLawrence V RubinsteinDavid R PattonP Mickey WilliamsStanley R HamiltonScott A KonoJames M FordAgustin A GarciaXingwei D SuiRobert D SiegelBrian M SlomovitzBarbara A ConleyCarlos L ArteagaLyndsay N HarrisPeter J O'DwyerAlice P ChenKeith T FlahertyPublished in: JCO precision oncology (2022)
mutation alone does not appear to be a sufficient predictor of taselisib activity.